Back to search results

Study of Povorcitinib and Ruxolitinib in Healthy Adults

This study is looking for healthy adults, aged 18 to 65, to help evaluate how two different medications, oral povorcitinib and topical ruxolitinib cream, are absorbed by the body. Researchers will use a special device called an open-flow microperfusion device to measure drug levels in the skin, as well as in the blood. The main goal is to understand how much of each drug gets into your system and how long it stays there. You can join if you are generally healthy, have a BMI between 18.0 and 30.5, and can swallow oral medication. The study plans to enroll 24 participants.

Study design
This is an interventional study involving 24 healthy adult participants. It is not specified if the study is randomized or blinded.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Drug levels will be measured for up to 12 days after the last dose.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07588139

A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult Participants

Recruiting
PHASE1Ages 18–65InterventionalTreatment
Incyte Corporation
~24 participants
Updated 2026-06-03 on ClinicalTrials.gov
What's tested:PovorcitinibRuxolitinib

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Pharmacokinetics Parameter (PK): Cmax of dermal interstitial fluid (dISF) ruxolitinib
Measured over Up to Day 12
+11 more outcomes measured

Conditions

Healthy Participants

Explore related trials

Healthy Volunteers

NCT07588139

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Axis Clinicals

    Dilworth, Minnesotano site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Incyte Medical Monitor · STUDY_DIRECTOR · Incyte Corporation

Who to contact

Incyte Corporation Call Center (US)
[email protected]
1.855.463.3463
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Ability to comprehend and willingness to sign a written ICF for the study.
Aged 18 to 65 years, inclusive, at the time of signing the ICF.
Body mass index between 18.0 and 30.5 kg/m2, inclusive.
No clinically significant findings on screening evaluations (clinical, laboratory, and ECG).
Ability to swallow and retain oral medication.
Willingness to avoid pregnancy or fathering children.

Exclusion

History of uncontrolled or unstable cardiovascular, respiratory, renal, gastrointestinal, endocrine, hematopoietic, psychiatric, and/or neurological disease within 6 months of screening.
Participants with any history of an autoimmune disease diagnosis.
History of cardiovascular, cerebrovascular, peripheral vascular, or thrombotic disease or uncontrolled hypertension.
History or presence of an abnormal ECG.
Presence or history of a malabsorption syndrome possibly affecting drug absorption (eg, Crohn's disease or chronic pancreatitis).
Any malignancies or history of malignancies with the exception of adequately treated or excised nonmetastatic basal cell or squamous cell cancer of the skin, or cervical carcinoma in situ.
Current or recent (within 3 months of screening) clinically significant gastrointestinal disease or surgery (including cholecystectomy; excluding appendectomy and hernia repair) that could affect the absorption of study drug.
Any major surgery within 4 weeks of screening.
Donation of blood to a blood bank or participation in a clinical study (except a screening visit) within 4 weeks of screening (within 2 weeks for plasma-only donation).
Blood transfusion within 4 months of check-in (Day -1).
Chronic or current active infectious disease requiring systemic antibiotic, antifungal, or antiviral treatment (includes latent treated tuberculosis).
Known tuberculosis infection that is active or participant-reported history of tuberculosis or treatment thereof.
Positive test for HBV, HCV, or HIV. Participants whose results are compatible with prior immunization for or immunity due to infection with HBV may be included at the discretion of the investigator.
Has received a live vaccine (including attenuated) or anticipation of need for such a vaccine during the study within 3 months prior to the first dose of study drug. Note: Examples of live vaccines include but are not limited to the following: measles, mumps, rubella, chickenpox/zoster, yellow fever, rabies, Bacillus Calmette-Guérin, and typhoid. Seasonal influenza vaccines for injection are generally killed-virus vaccines and are allowed; however, intranasal influenza vaccines are live, attenuated vaccines and are not allowed.
Medical or self-reported history of alcoholism within 3 months of screening.
History of significant alcohol use within 3 months of screening, defined as regular alcohol consumption \> 21 units per week for males and \> 14 units for females (1 unit = 8 oz of beer or a 25 mL shot of 40% spirit, 1.5 to 2 units = 125 mL glass of wine, depending on type).
Positive urine or breath test for ethanol or positive urine or serum screen for drugs of abuse that are not otherwise explained by permitted concomitant medications or diet.
Current treatment or treatment within 30 days or 5 half-lives (whichever is longer) before the first dose of study treatment with another investigational medication or current enrollment in another investigational drug study.
Current treatment or treatment within 15 days or 5 half-lives (whichever is longer) before the first dose/application of study treatment with strong inducers or strong and moderate inhibitors of CYP3A4, P-gp, or BCRP (refer to the Drug Interaction Database for prohibited drugs.
Consumption of red wine, Seville oranges, grapefruit or grapefruit juice, pomelos, exotic citrus fruits, grapefruit hybrids, or fruit juices within 72 hours before the first dose of study drug.
History of any significant drug allergy (such as anaphylaxis or hepatotoxicity) deemed clinically relevant by the investigator.
Known hypersensitivity or severe reaction to povorcitinib or any excipients of povorcitinib, to ruxolitinib or any excipients of ruxolitinib or any JAK inhibitors.
Inability to undergo venipuncture or tolerate venous access.
History of tobacco or nicotine containing product use within 1 month of screening.
Use of prescription drugs (including hormonal contraceptives) within 14 days of study treatment administration/application or nonprescription medications/products (including vitamins, minerals, and phytotherapeutic/herbal/plant-derived preparations) within 7 days before study treatment administration/application. However, occasional and standard dose paracetamol, acetaminophen, ibuprofen, and standard dose vitamins are permitted. Mega dose vitamins or supplements are not permissible.
Women who are pregnant or breastfeeding.
Any condition that would interfere with full participation in the study, including administration/application of study treatment and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.
Excessive exercise (ie Iron man®, triathlon, etc) within 7 days before check-in (Day -1).
Tattoo or scarring at skin sample sites.
Participants prone to keloid or hypertrophic scar formation or any known wound healing disorder.
Not willing to avoid excessive sun exposure, steam baths, sauna, swimming, and other strenuous activities for 14 days after Day 12 to ensure good tissue regeneration.
Pronounced hairiness on the planned application sites, dOFM probe insertion sites, and skin biopsy collection sites, that may negatively affect dose application, probe placement, and/or sample testing.
Not willing to refrain from shaving the planned application sites, dOFM probe insertion sites, and skin biopsy collection sites, or using skin care products on the planned application sites, dOFM probe insertion sites, and skin biopsy collection sites, for at least 5 days before Day 1.
Not willing to avoid sunbathing, using tanning salons, or using spray/lotion tanning agents within 7 days prior to Day 1 dose administration/application.
Presence of needle phobia.
Increased risk of thrombosis (eg, personal or first-degree relative\[s\] history of deep vein thrombosis).

What this trial measures

  • Pharmacokinetics Parameter (PK): Cmax of dermal interstitial fluid (dISF) ruxolitinibUp to Day 12

    Defined as the maximum observed plasma concentration.

  • Pharmacokinetics Parameter: AUClast of dISF ruxolitinibUp to Day 12

    Defined as the area under the concentration-time curve from time zero to the last quantifiable concentration.

  • Pharmacokinetics Parameter: AUC∞ of dISF ruxolitinibUp to Day 12

    Defined as the area under the plasma concentration-time curve extrapolated to time of infinity.

  • Pharmacokinetics Parameter: Cmax of dISF povorcitinibUp to Day 12

    Defined as the maximum observed plasma concentration.

  • Pharmacokinetics Parameter: AUClast of dISF povorcitinibUp to Day 12

    Defined as the area under the concentration-time curve from time zero to the last quantifiable concentration.

  • Pharmacokinetics Parameter: AUC∞ of dISF povorcitinibUp to Day 12

    Defined as the area under the plasma concentration-time curve extrapolated to time of infinity.

  • Pharmacokinetics Parameter: Cmax of plasma ruxolitinibUp to Day 12

    Defined as the maximum observed plasma concentration.

  • Pharmacokinetics Parameter: AUClast of plasma ruxolitinibUp to Day 12

    Defined as the area under the concentration-time curve from time zero to the last quantifiable concentration.

  • Pharmacokinetics Parameter: AUC∞ of plasma ruxolitinibUp to Day 12

    Defined as the area under the plasma concentration-time curve extrapolated to time of infinity.

  • Pharmacokinetics Parameter: Cmax of plasma povorcitinibUp to Day 12

    Defined as the maximum observed plasma concentration.

  • Pharmacokinetics Parameter: AUClast of plasma povorcitinibUp to Day 12

    Defined as the area under the concentration-time curve from time zero to the last quantifiable concentration.

  • Pharmacokinetics Parameter: AUC∞ of plasma povorcitinibUp to Day 12

    Defined as the area under the plasma concentration-time curve extrapolated to time of infinity.